首页> 外文期刊>Nature >A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
【24h】

A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns

机译:基于基因组重排模式的胰腺癌进化新模型

获取原文
获取原文并翻译 | 示例
       

摘要

Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the classically held view of stepwise cancer development(1). The current model of tumorigenesis, based on analyses of precursor lesions, termed pancreatic intraepithelial neoplasm (PanINs) lesions, makes two predictions: first, that pancreatic cancer develops through a particular sequence of genetic alterations(2-5) (KRAS, followed by CDKN2A, then TP53 and SMAD4); and second, that the evolutionary trajectory of pancreatic cancer progression is gradual because each alteration is acquired independently. A shortcoming of this model is that clonally expanded precursor lesions do not always belong to the tumour lineage(2,5-9), indicating that the evolutionary trajectory of the tumour lineage and precursor lesions can be divergent. This prevailing model of tumorigenesis has contributed to the clinical notion that pancreatic cancer evolves slowly and presents at a late stage(10). However, the propensity for this disease to rapidly metastasize and the inability to improve patient outcomes, despite efforts aimed at early detection(11), suggest that pancreatic cancer progression is not gradual. Here, using newly developed informatics tools, we tracked changes in DNA copy number and their associated rearrangements in tumour-enriched genomes and found that pancreatic cancer tumorigenesis is neither gradual nor follows the accepted mutation order. Two-thirds of tumours harbour complex rearrangement patterns associated with mitotic errors, consistent with punctuated equilibrium as the principal evolutionary trajectory(12). In a subset of cases, the consequence of such errors is the simultaneous, rather than sequential, knockout of canonical preneoplastic genetic drivers that are likely to set-off invasive cancer growth. These findings challenge the current progression model of pancreatic cancer and provide insights into the mutational processes that give rise to these aggressive tumours.
机译:胰腺癌是一种高度侵袭性的肿瘤类型,预后普遍较差,是经典的逐步发展癌症观点(1)。基于对前体病变(称为胰腺上皮内肿瘤(PanINs)病变)的分析,当前的肿瘤发生模型做出两个预测:首先,胰腺癌通过特定的基因改变序列发展(2-5)(KRAS,其次是CDKN2A ,然后是TP53和SMAD4);第二,胰腺癌进展的发展轨迹是渐进的,因为每种改变都是独立获得的。该模型的缺点是克隆扩展的前体病变并不总是属于肿瘤谱系(2,5-9),这表明肿瘤谱系和前体病变的进化轨迹可能是不同的。这种流行的肿瘤发生模型促成了胰腺癌发展缓慢并出现在晚期的临床观念(10)。然而,尽管努力尽早发现该疾病,但该疾病迅速转移的趋势以及无法改善患者预后的能力(11)提示,胰腺癌的进展并非循序渐进。在这里,我们使用最新开发的信息学工具,追踪了富含肿瘤的基因组中DNA拷贝数的变化及其相关的重排,发现胰腺癌的发生既不是渐进的,也不是遵循公认的突变顺序。三分之二的肿瘤具有与有丝分裂错误有关的复杂重排模式,与作为主要进化轨迹的标点均衡相一致(12)。在少数情况下,此类错误的后果是同时(而不是连续)剔除可能导致侵袭性癌症生长的规范肿瘤前遗传驱动因素。这些发现挑战了当前胰腺癌的进展模型,并为引起这些侵袭性肿瘤的突变过程提供了见识。

著录项

  • 来源
    《Nature》 |2016年第7625期|378-382|共5页
  • 作者单位

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Univ Hlth Network, Dept Pathol, UHN Program BioSpecimen Sci, Toronto, ON M5G 2C4, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada;

    Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada|Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S IA8, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3G4, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Univ Hlth Network, Dept Pathol, UHN Program BioSpecimen Sci, Toronto, ON M5G 2C4, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Hlth Network, Dept Pathol, UHN Program BioSpecimen Sci, Toronto, ON M5G 2C4, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada|Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Surg Oncol, Toronto, ON M4N 3M5, Canada;

    Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA;

    Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada|Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3H 2L9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada;

    Los Alamos Natl Lab, Theoret Biol & Biophys T6, Los Alamos, NM 87545 USA|Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM 87545 USA;

    Spanish Natl Canc Res Ctr CNIO, Epithelial Carcinogenesis Grp, Madrid 28029, Spain;

    Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada|Univ Hlth Network, Dept Surg, Toronto, ON M5G 2C4, Canada;

    Univ Hlth Network, Dept Pathol, UHN Program BioSpecimen Sci, Toronto, ON M5G 2C4, Canada|Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada;

    Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England|Univ Cambridge, Dept Haematol, Cambridge CB2 0XY, England;

    Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada|Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:52:17

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号